Sarepta Therapeutics (SRPT) – Research Analysts’ Weekly Ratings Updates

Sarepta Therapeutics (NASDAQ: SRPT) recently received a number of ratings updates from brokerages and research firms:

• 10/13/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/8/2026 – Sarepta Therapeutics had its price target lowered by Royal Bank Of Canada from $19.00 to $17.00. They now have a “sector perform” rating on the stock.
• 10/5/2026 – Sarepta Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/5/2026 – Sarepta Therapeutics had its “sell” rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
• 9/30/2026 – Sarepta Therapeutics had its price target lowered by JPMorgan Chase & Co. from $23.00 to $20.00. They now have a “neutral” rating on the stock.
• 9/28/2026 – Sarepta Therapeutics had its “underperform” rating reaffirmed by Needham & Company LLC.
• 9/24/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/23/2026 – Sarepta Therapeutics was upgraded by William Blair to “hold”.
• 9/9/2026 – Sarepta Therapeutics had its “sell” rating reaffirmed by Benchmark Co..
• 9/8/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/19/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.